Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H16ClF3N4O3 |
| Molecular Weight | 467.843 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[2H]C([2H])([2H])NC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
InChI
InChIKey=MLDQJTXFUGDVEO-FIBGUPNXSA-N
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
Donafenib (CM-4307) is a derivative of sorafenib, where [1H] hydrogens on the terminal methyl group are substituted by deuterium. The drug was developed by the Chinese company Suzhou Zelgen Biopharmaceuticals. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, donafenib may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Donafenib is being investigated in phase 3 clinical trials for the treatment of 131I-refractory differentiated thyroid cancer, advanced hepatocellular carcinoma, and metastatic colorectal cancer.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
||
|
NCI_THESAURUS |
C2336
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1130115-44-4
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
25191001
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
100000183796
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
C118294
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
DB15414
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
DONAFENIB
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | MedKoo CAT NO.: 206144; Description: Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC). (Last update: 8/21/2015). | ||
|
DTXSID90648995
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY | |||
|
41XGO0VS1U
Created by
admin on Sat Dec 16 12:08:09 GMT 2023 , Edited by admin on Sat Dec 16 12:08:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
